Title:
DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS
Document Type and Number:
WIPO Patent Application WO/2023/083291
Kind Code:
A1
Abstract:
The present invention relates to compounds of formula I and formula II and the use thereof in the treatment of metabolic diseases such as liver fibrosis and non-alcoholic hepatitis. Specifically, provided are the compounds as shown, and pharmaceutically acceptable salts or esters, prodrugs, stereoisomers, hydrates, solvates, crystal forms and metabolite forms thereof, or any combination or mixture thereof in the preparation of a drug or a reagent, the drug being used for at least one of the following: A-(L1)x-A'(formula I); A1-(L1)x-A1'(formula II)
Inventors:
GAO JIE (CN)
CHENG HUIMIN (CN)
CHENG JUN (CN)
ZHANG PEIYU (CN)
CHENG HUIMIN (CN)
CHENG JUN (CN)
ZHANG PEIYU (CN)
Application Number:
PCT/CN2022/131311
Publication Date:
May 19, 2023
Filing Date:
November 11, 2022
Export Citation:
Assignee:
SHENZHEN LIWO BIO PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
C07C219/08; A61K31/223; A61P1/06; C07K5/062
Domestic Patent References:
| WO2006101940A2 | 2006-09-28 |
Foreign References:
| CN111084769A | 2020-05-01 | |||
| CN102807602A | 2012-12-05 | |||
| CN106632605A | 2017-05-10 |
Other References:
CHEN HAORAN, SUN YUE, ZHAO HAIDING, QI XIAOFEN, CUI HUI, LI QIMING, MA YING: "α-Lactalbumin peptide Asp-Gln-Trp alleviates hepatic insulin resistance and modulates gut microbiota dysbiosis in high-fat diet-induced NAFLD mice", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 13, no. 19, 3 October 2022 (2022-10-03), GB , pages 9878 - 9892, XP093067193, ISSN: 2042-6496, DOI: 10.1039/D2FO01343F
ZHOU, L. ET AL.: "Aspartate reduces liver inflammation and fibrosis by suppressing the NLRP3 inflammasome pathway via upregulating NS3TP1 expression.", BIORXIV, 28 June 2022 (2022-06-28), pages 1 - 35, XP093067201
CANBAY ALI, SOWA JAN-PETER: "l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 79, no. S1, 1 February 2019 (2019-02-01), NZ , pages 39 - 44, XP093067204, ISSN: 0012-6667, DOI: 10.1007/s40265-018-1020-5
BUTTERWORTH ROGER F., CANBAY ALI: "Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease", DIGESTIVE DISEASES: CLINICAL REVIEWS, S. KARGER AG, CH, vol. 37, no. 1, 1 January 2019 (2019-01-01), CH , pages 63 - 68, XP093067210, ISSN: 0257-2753, DOI: 10.1159/000491429
DATABASE Registry 2009-09-04, ANONYMOUS : "L-Aspartic acid, 1,1'-(1,4- butanediyl) 4,4'-bis (1,1-dimethylethyl) ester", XP093067434, retrieved from STN Database accession no. 1180655-51-9
ZHOU, L. ET AL.: "Aspartate reduces liver inflammation and fibrosis by suppressing the NLRP3 inflammasome pathway via upregulating NS3TP1 expression.", BIORXIV, 28 June 2022 (2022-06-28), pages 1 - 35, XP093067201
CANBAY ALI, SOWA JAN-PETER: "l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 79, no. S1, 1 February 2019 (2019-02-01), NZ , pages 39 - 44, XP093067204, ISSN: 0012-6667, DOI: 10.1007/s40265-018-1020-5
BUTTERWORTH ROGER F., CANBAY ALI: "Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease", DIGESTIVE DISEASES: CLINICAL REVIEWS, S. KARGER AG, CH, vol. 37, no. 1, 1 January 2019 (2019-01-01), CH , pages 63 - 68, XP093067210, ISSN: 0257-2753, DOI: 10.1159/000491429
DATABASE Registry 2009-09-04, ANONYMOUS : "L-Aspartic acid, 1,1'-(1,4- butanediyl) 4,4'-bis (1,1-dimethylethyl) ester", XP093067434, retrieved from STN Database accession no. 1180655-51-9
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: